Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

EmbraceRX vs Layla

EmbraceRX
Graded #363

Lower grade

vs+12.300000000000004
Layla
Graded #101

Higher grade

The verdict

Layla takes it — 70.9/100 to 58.6/100.

Layla grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Layla is a US telehealth weight-loss program built around semaglutide, offering compounded semaglutide as injections and as oral dropper drops, plus compounded tirzepatide and a brand-inclusive GLP-1…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLayla +21
45
66
Dose & formulationLayla +40
56
96
Clinical oversightEven
76
76
Labs & monitoringEven
52
52
FulfillmentEmbraceRX +8
73
65
Contract termsEven
55
55
EmbraceRX · left barLayla · right bar

The numbers

MetricEmbraceRXLayla
WeighScore58.6/10070.9/100
GradeCC
Scorecard rank#363#101
SemaglutideNot disclosed$237/mo (all doses, compounded)
TirzepatideNot disclosed$199/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
EmbraceRX

Graded #363 · C

Strengths

  • Broad compounded GLP-1 menu — semaglutide (+B12), tirzepatide, oral semaglutide/tirzepatide capsules, plus Lipo-B
  • Large peptide/longevity catalog (BPC-157, GHK-Cu, NAD+, MOTS-C) across injectable, oral, topical, and nasal formats
  • Clinician-guided, compounded at FDA-registered pharmacies; partners with a licensed physician network (Samaritan MD)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, CCPA, Returns & Refunds)

Where it loses points

  • Pricing not shown upfront — revealed only at checkout after a dose selection
  • Offers investigational/research compounds (e.g., retatrutide, AOD-9604) that are not FDA-approved
  • Compounding pharmacy partner not named ('FDA-registered pharmacies')
  • Not LegitScript-certified (no certification displayed)
Layla

Graded #101 · C

Strengths

  • Oral semaglutide dropper option plus injectable semaglutide and tirzepatide, with a brand-name upgrade path
  • Named Medical Director (Dr. Ruth Cohen) and 24-7 doctor messaging
  • Quiz-based intake with fast three to five day shipping

Where it loses points

  • Brand-inclusive GLP-1 program is expensive, starting around 1,299 dollars
  • States served are not published on the site
  • Support phone line uses a UK format, and the compounding pharmacy is not named

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard